PCSK9 and diabetes mellitus: Explanations for this discrepancy include the short trial duration, and the possibility that the risk of new-onset diabetes depends on an intracellular reduction of PCSK9 (which results from genetic variation in the PCSK9 gene, but not from treatment with antibodies binding only extracellular PCSK9).